UK markets close in 5 hours 26 minutes

TherapeuticsMD, Inc. (TXMD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.61-0.06 (-0.90%)
At close: 04:00PM EDT
6.40 -0.21 (-3.18%)
Pre-market: 04:10AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 63.15M
Enterprise value 136.73M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.63
Price/book (mrq)40.75
Enterprise value/revenue 1.49
Enterprise value/EBITDA -23.46

Trading information

Stock price history

Beta (5Y monthly) 1.54
52-week change 3-80.84%
S&P500 52-week change 3-14.73%
52-week high 341.00
52-week low 31.99
50-day moving average 38.35
200-day moving average 311.34

Share statistics

Avg vol (3-month) 3482.85k
Avg vol (10-day) 370.01k
Shares outstanding 59.47M
Implied shares outstanding 6N/A
Float 87.1M
% held by insiders 111.40%
% held by institutions 142.27%
Shares short (14 Sept 2022) 4367.55k
Short ratio (14 Sept 2022) 41.49
Short % of float (14 Sept 2022) 43.93%
Short % of shares outstanding (14 Sept 2022) 43.90%
Shares short (prior month 14 Aug 2022) 4620.66k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:50
Last split date 308 May 2022

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin -29.48%
Operating margin (ttm)-117.40%

Management effectiveness

Return on assets (ttm)-37.83%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)91.98M
Revenue per share (ttm)10.70
Quarterly revenue growth (yoy)24.20%
Gross profit (ttm)68.11M
EBITDA -103.81M
Net income avi to common (ttm)-27.12M
Diluted EPS (ttm)-21.73
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)26.3M
Total cash per share (mrq)2.79
Total debt (mrq)99.88M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.60
Book value per share (mrq)-2.94

Cash flow statement

Operating cash flow (ttm)-122.71M
Levered free cash flow (ttm)-65.57M